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Background: Understanding how sexual dimorphism affects the physiological and pathological responses of the
immune system is of considerable clinical importance and could lead to new approaches in therapy. Sexual
dimorphism has already been noted as an important factor in autoimmune diseases: the aim of this study was to
establish whether sexual dimorphism in autoimmune diseases is the result of differing pathways being involved in
the regulation of T-helper (Th) cell network homeostasis.
Methods: We focused on sexually dimorphic changes in the immune response in multiple sclerosis (MS) patients in
order to ascertain how these alterations relate to the pathway regulation of the cytokine homeostasis and the Th
cell networks. We studied antigen presenting cell (APC)-dependent T cell activation in groups of healthy subjects, in
patients under interferon (IFN) β-therapy and untreated. Cytokines, soluble (s) CD30 and the expanded disability
status scale (EDSS) were used as biomarkers for T cell differentiation and neurological deficit.
Results: The data confirm our belief that sexual dimorphism in autoimmune diseases is the result of differing
pathways that regulate Th cell network homeostasis: interleukin (IL) 6 pathways in women and IFNγ pathways in
men. Given the increased susceptibility of women to MS and the significance of IL6 in the autoimmune process
compared to IFNγ, it is logical to assume that IL6 pathways are in some way implicated in the prevalence of
autoimmune diseases in women. Indeed, our data indicate that IL6 pathways are also involved in T regulatory
(Treg) cell imbalance and an increase in neurological deficit in both men and women groups of MS patients,
underlining the autoimmune etiology of multiple sclerosis. In further support of differing cytokine pathways in men
and women, we noted that the efficacy of IFNβ-treatment in the re-establishment of Th-network balance and in
the delaying of the neurological disability progression is linked to the IL6 pathway in women, but to the IFNγ
pathway in men. Lastly, we also identified specific gender biomarkers for the use in therapy.
Conclusions: The identification of gender-specific drugs is of considerable importance in translational medicine
and will undoubtedly lead to more appropriate therapeutic strategies and more successful treatment.
Keywords: Gender differences, Autoimmune diseases, Multiple sclerosis, Th cytokine networks, Th cell networks,
CD30, Clinical targets, Clinical biomarkersBackground
Sexual dimorphism in disease susceptibility is of consid-
erable clinical importance and raises the question of
gender specific drugs. The understanding of the physio-
logical and pathological roles of sexual dimorphism in
the immune response will clearly lead to improved
gender-specific clinical therapy strategies. Autoimmune
diseases highlight the need for further research in this* Correspondence: annamaria.berghella@cnr.it
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reproduction in any medium, provided the orfield to better understand the reason why a large num-
ber of autoimmune diseases occur more frequently in
women than men, such as MS. This female preponder-
ance for abnormal autoimmune function has largely
gone unexplained. There is evidence that sex hormones
can affect the immune system and that female and male
hormones act in opposing ways [1,2]. For example, Th1
and Th2 responses appear affected by androgenic and
estrogenic preponderance, respectively: androgens favor
the development of a Th1 response and the activation of
CD8 cells [3], while estrogens seem to direct theal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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phocytes are activated and antibody production
flourishes [2]. Pregnancy, a high estrogen state, is of
course characterized by Th2 preponderance, and a fail-
ure in the establishment of the Th2 dominance has been
associated with increased risk for pregnancy loss [4,5].
However, the basic reasons for the gender bias are not
clear.
In the early 1980s, the Th1-Th2 hypothesis was put for-
ward [6,7]: Th1 lymphocytes secrete pro-inflammatory
cytokines (e.g. IL-2, IFNγ IL-12, and lymphotoxin) and they
are specific against viruses and intracellular pathogens;
whereas, Th2 cells secrete anti-inflammatory cytokines
(e.g. IL-4, IL6, IL-5, IL-10) and act against extracellular
pathogens, mediating humoral immune responses [7,8].
Subsequent research made it clear that the cytokine envir-
onment at the time of CD4+ Tcell activation was the deter-
mining key in generating these effector subsets, due to the
ability of cytokines to activate tailored transcription factors
required for the differentiation of the specific Th subsets:
Th1 requires the expression of T bet transcription factor;
whereas, Th2 cells are controlled by expression of GATA-3
[9-11]. This concept led to the identification of other Th
subsets with distinct functions in the immune response,
namely Treg cells, Th17 cells and Th9 cells.
Treg cells produce the transforming growth factor
(TGF) β cytokine, maintain Th cell network homeostasis
and peripheral immunological tolerance. Forkhead box
P3 (Foxp3), a member of the forkhead/winged-helix fam-
ily of transcription factors, acts as a “master” regulator
for the development and function of Treg cells and its
constitutive expression is necessary for the specific role
of Tregs. The mutation or deficiency of Foxp3+ Tregs
cells is a key factor in the development of autoimmune
diseases and the inability of the immune system to regu-
late the homeostasis in T-cell activation effectively
[12,13].
Th17 cells secrete IL-17A and IL-17F, they arise in
response to a combination of TGFβ plus IL6 pro-
inflammatory cytokines and are controlled by the expres-
sion of the transcription factor retinoic acid-related
orphan receptor gt (RORgt) [14-16]. The transcription fac-
tor of the more recently discovered Th9 subset [17,18],
producing IL9 cytokine, is still to clarify. These cells
develop from naive CD4 precursors in response to TGFβ
plus IL-4 cytokines [17,18].
MS is an autoimmune inflammatory demyelinating dis-
order of the central nervous system. Gender influences
both the susceptibility and the clinical course of MS: in
fact the disease is more common in women than in men
and there is an increased proportion of men developing
the primary progressive form of MS [19]. The basis for
these differences may include immunological factors but
the exact mechanism has not yet been established.There is a definite need for more effective biomarkers
and therapeutic targets in MS. IFNβ therapy is only par-
tially effective and not in all MS patients. IFNβ therapy
can reduce the severity and frequency of relapses, dis-
ease activity (as measured by magnetic resonance im-
aging) [20,21], and disability (as measured by EDSS
scores) by inducing mechanisms that determine a fall in
sCD30 levels and a re-establishment of homeostasis in
the Th-cell network [22-24].
On the basis of the above we investigated the possibil-
ity that sexual dimorphism in autoimmune diseases
could depend on sexual dimorphism in the regulation of
Th cell network homeostasis. We carried out studies
using the peripheral blood of healthy subjects, IFNβ-
treated and untreated relapsing remitting (RR) MS
patients, as independent cohorts. We used systems biol-
ogy to study APC-dependent T cell activation. Cyto-
kines, sCD30 and EDSS parameters, biomarkers of
direction in T cell differentiation and neurological def-
icit, were used to relate male and female gender to the
cytokine pathways regulation of Th cell differentiation.
Methods
Experimental design
In physiological systems the different components operate
as a network: they vary dynamically and co-vary each
other respectively. Therefore, the identification of physio-
logical pathways can only be achieved through evaluations
of the systems biology characteristics. Due to the complex-
ity of biological systems, this process requires the use of
mathematical models that provide a framework for deter-
mining the outcome of numerous and simultaneous time-
dependent and space-dependent processes [25-27].
We designed an experimental approach based on the
use of cytokine data-driven models of the immune
response. All persons gave their informed consent prior
to their inclusion in the study.
We used the levels of Th cytokines produced by APC
(IFNy, IL6, IL10) as biomarkers of Th cell differentiation:
the relative proportion of each Th cell-type generation
depends, in fact, on the relative proportion of specific
cytokines produced by APCs and released into the cell
environment during resting and activation states of the
immune response.
To investigate whether sexual dimorphism of Th cyto-
kine pathways and regulation of Th cell network homeo-
stasis are normally present in the immune response, we
determined the profiles of the levels of Th cytokines in
the supernatants of 72 h whole blood cultures without
activation (APC and T cells in resting conditions), with
lipopolysaccharide (LPS) (activated APCs) and phyto-
haemagglutinin (PHA) (activated T cells) stimuli, in
healthy subjects. We also analyzed the PHA-level of
cytokine network profiles in supernatants of 24 h
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blood mononuclear cells (PBMC), in order to discover
how T cellular components affect the cell network
interactions.
To establish whether sexual dimorphism in autoimmune
diseases depends on differences in the pathways responsible
for the regulation of Th cell network homeostasis, we deter-
mined, in treated and untreated RRMS patients, Th cytokine
profiles in culture supernatants of: i) immature (I) dendritic
cells (DC), to study the APC regulation of Th pathways in
immune resting conditions; ii) DC after LPS stimulus, to
study APC regulation of Th pathways in activated condi-
tions; iii) whole blood without activation (APC and T cells
in resting conditions), and after PHA stimulus (activated T
cells), in order to clarify APC and Th cell interaction.
The cytokines used as biomarkers in the immune
response models were: IL2, IL12p70, IFNy, IL4, IL12p40,
IL6, IL10 and TGFβ. IL2, IL12p70 and IFNy support
Th1 functions [28] promoting cell mediated immunity;
IL12p40, IL4, IL6 and IL10 are associated with Th2
responses and IL10 is a powerful inhibitor of IFNγ and
macrophages [29]. TGFβ together with IL6 also supports
Th17 functions (suppressing Th1 functions) [30,31],
whereas TGFβ together with IL4 supports Th9 functions
[32]; IFNy inhibits Th9 functions [32].
sCD30 was used as a biomarker for homeostasis or
alteration in immunological and neurological pathways
to evaluate the success or failure treatment. In fact, our
recent results indicate that the up- and down-regulation
of sCD30 levels within physiological ranges is a bio-
marker for homeostasis in immunological and neuro-
logical pathways and therapeutic success. However a
significant increase in sCD30 levels suggests immuno-
logical alterations, neurological deficit and treatment
failure [22]. Our results underlined that sCD30 pathways
control immunological and neurological system homeo-
stasis by regulating the type of Th differentiation
through the cytokine profiles of IDCs and DCs, which
are major professional APCs that initiate and modulate
immune response by inducing Th0 differentiation [22].
Healthy subjects
A group of 66 healthy subjects (33 men and 33 women:
blood donors, laboratory staff and relative) were studied.
None of the subjects was receiving concurrent drug treat-
ment including widely-used pharmaceuticals, such as sali-
cylates and sex hormones (contraceptive pill, hormone
replacement therapy). Distribution of age in male and
female groups was the same (mean ± SD = 41±12 years,
compared to mean ± SD = 41 ± 15 years, p = 0.14).
Independent validation cohorts of multiple sclerosis patients
We investigated 36 patients with clinically defined
RRMS, admitted to the MS Center of the Department ofNeurology of the University of L’Aquila. 18 of these
patients were receiving IFNβ-therapy (the treated group)
and 18 were not (the untreated group). None of the
patients had suffered an exacerbation in the 3 months
before entry into the study or received corticosteroids in
EDSS. Neurological examinations were carried out by
neurologists from the MS Center of the Department of
Neurology of the University of L’Aquila. EDSS was used
to assess patient neurological deficit as MS is a chronic,
lifelong disease and long term deficit data need to be
evaluated. We considered the absence of clinical relapses
of at least 3 months, a marker of disease inactivity. The
treated group consisted of 5 men and 13 women, with a
mean age ± SE of 34.3 ± 2.2 and of 31 ± 1.8 years
respectively; and a mean EDSS score ± SE of 1.8 ± 0.6
and 2.2±0.3 respectively; All had been receiving IFNβ1 a
treatment [22 μg (4 patients, 1 men and 3 women) or 44 μg
(14 patients, 4 men and 10 women] subcutaneously thrice
weekly for a mean period±SE of 27.5 ± 1.4 months (range:
2 to 60 months]. The untreated group of patients, matched
for sex (p = 0.6), age (p = 0.3) and EDSS (p = 0.9) score,
consisted of 7 men and 11 women with a mean age±SE of
37.2 ± 4.7 and of 32 ± 9.1 respectively; and a mean EDSS
score±SE of 1.9 ± 0.4 and of 2 ± 0.3 respectively. Distribu-
tion of age, EDSS, treatment dose and period of treatment
in male and female groups was the same not only within,
but also between the groups of treated and untreated
patients. This was a paired samples study: all parameters
were determined for each patient sample.
Blood samples
Blood was collected at the same time of day to minimize
the effects of diurnal variation.
Whole blood cell cultures
The whole blood culture method [33] was used since it
reflects in vivo physiological conditions more accurately
[34]. Briefly, a 15 ml sample of heparinized blood (20 IU
heparin/ml blood Liquemin Roche) was taken from each
subject, and the samples, kept at room temperature,
were used immediately. Venous blood was diluted 1:10
with RPMI 1640 medium (Sigma, endotoxin tested),
which was supplemented with 0.2 mM of L glutamine,
50 IU/ml of penicillin, 50 μg/ml of streptomycin (Sigma)
and 10% of heat-inactivated serum. Aliquots at 1 × 106
cells were distributed in 12 mm polypropylene tubes.
10 μg/ml of PHA (Sigma) and 10 μg/ml of LPS (Sigma)
were used for stimulation and aliquots without stimuli
were also prepared. After 3 days of culture the super-
natant was removed to be assayed for cytokine levels
and stored in aliquots at −80°C until used. The effect of
adding heparin, which prevents clotting in whole blood
cultures, was tested (data not shown). Experimental con-
ditions were: with stimuli (+PHA and +LPS) in order to
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to evaluate immune response in resting conditions.
PHA was used to study T cell contribution [35] and
LPS to evaluate the influence of antigen presenting
cells [36].
PBMC cell cultures
PBMC were separated by centrifugation over a Ficoll/
Hypaque gradient (20 min, 1000 g), and washed with
RPMI-1640 medium (Gibco). Isolated cells were cul-
tured at a concentration of 1 × 106 cells/ml in RPMI-
1640 complete medium (supplemented with 10% of fetal
calf serum, L-glutamine 0.2 nM, penicillin 50 UI/ml,
streptomycin 50 g/ml; Sigma). Supernatants were
obtained from PBMC cultures in RPMI-1640 complete
medium. The cells (with and without: PHA, 3 g/ml or
LPS, 10 g/ml) were incubated at concentrations of 1×106
cells/ml at 37°C in a humidified atmosphere of 5% CO2.
After 24 h of culture without a change of medium,
supernatant was removed from each well, centrifuged at
250 g and stored in aliquots at −80°C until use.
Generation of DCs from monocytes
A sample of heparinized blood (20 IU/ml blood -
Liquemin-Roche) was taken from each subject and diluted
1:4 with medium at room temperature. PBMCs were sepa-
rated by centrifugation (160 g for 20 minutes at 20°C) over
a Lymphoprep gradient (Nycomed Norvay). PBMCs were
recovered from plasma/Lymphoprep interface, washed
three times with medium (200 g for 10 minutes at 20°C).
Monocytes from PBMC samples were obtained by
removing T cells, B cells, NK cells and granulocytes
(if present): antibody mix was added to the PBMC sam-
ple and then depletion Dynabeads were added to capture
the antibody bound cells. Dynabeads are uniform, super-
magnetic, polystyrene beads coated with a Fc specific
human IgG4 antibody against mouse IgG. The antibody
mix contained a mixture of mouse monoclonal antibody
for CD2, CD7, CD16 (specific for CD16a and CD16b),
CD19 and CD56. The blocking reagent was gamma
globulin to block Fc receptors (FcR) on monocytes.
These coated cells were then separated with a magnet
(Dynal MPC) and discarded. PBMCs were then trans-
ferred into a 15 ml tube, washed three times with PBS
by centrifugation (at 225 g for 8 minutes at 2-8°C) and
then re-suspended at 1 × 107 per 100–200 μl PBS. 22 μl
of blocking reagent and 20 μl of antibody mix for each
1 × 107 MNC cells were added and incubated for 10
minutes at 2-8°C. The cells were washed (by adding 1
ml of PBS per 1 × 107 MNC and centrifugation for
8 minutes at 500 g) and re-suspended in 0.9 ml of PBS per
1 × 107 MNC. 100 μl of Depletion Dynabeads per
1 × 107 MNC was added and incubated for 15 minutes
at 2-8°C with gentle tilting and rotation. The totalvolume for cell and bead incubation should be 1 ml
per 1 × 107 MNC. The rosettes were re-suspended by
careful pipetting 5–6 times before increasing the vol-
ume by adding 1–2 ml of PBS and placed in the Dynal
Magnetic particle concentrator for 2 minutes. Isolated
monocytes recovered were > 98% viable and free of
surface bound antibody or Dynabeads. Monocytes were
re-suspended in RPMI 1640 (Sigma, endotoxin tested)
complete medium containing 10% of AB male human
serum (heat-inactivated for 30 minutes at 56°C), peni-
cillin (50 UI/ml), streptomycin (50 μg/ml) and L-
glutamine (0.2 mM).
The cells were incubated in 24-well plates at a concen-
tration of 200,000 cells per ml at 37°C in a humidified
atmosphere of 5% CO2 for 8 days and stimulated with
30 ng/ml of recombinant IL4 (Preprotech-England, spe-
cific activity of > 5 × 106 U/mg), 30 ng/ml of recom-
binant GM-CSF (Preprotech-England, specific activity
of > 1 × 107 U/mg). On day 3, IL4 and GM-CSF were
added again and on day 6, immature DCs were obtained.
Immature DCs were stimulated with 100 μg/ml of LPS
(Sigma), and DCs without stimuli were also prepared.
After 2 days of culture the supernatant was removed from
each well, centrifuged at 250 g and stored frozen in
aliquots at ¬80°C until used.
Cytokine detection
Cytokine levels and soluble molecules were determined
using a solid phase sandwich ELISA method [37]. For
intra assay precision, samples of known cytokine con-
centration were assayed in replicates of 10 (to determine
precision within an assay) and the coefficient of vari-
ation is < 10% (data not shown). For inter assay preci-
sion, samples were assayed 30 times in multiple assays
(to determine precision between assays), the coefficient
of variation was < 10% (data not shown). The ELISA
assay sensitivity was: IL10 < 1 pg/ml, TGFβ1< 1.9 pg/ml,
IL2 < 10pg/ml, IFNγ< 5 pg/ml, IL6 < 2 pg/ml, (Euroclone),
IL12p40 < 15pg/ml, IL12p70 < 0.5 pg/ml, IL4<0.13 pg/ml
(R&D System), sCD30 < 0.5 U/ml, sBcl2 < 1 U/ml (Bender
Medsystem).
Data analysis
In physiological systems components operate as a net-
work and each component varies and co-varies dynamic-
ally with respect to one another. Therefore, the
identification of physiological pathways, and correlated
biomarkers can only be achieved through evaluations
that take these fluctuations into account. Hence we used
systems biology studies [38,39] which allowed us to
analyze the relationships between parameters (levels of
cytokines, sCD30 and EDDS values) and the behaviour
of this multicomponent system as a network. Thus, in
addition to the study of statistical differences using the
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we used multivariate statistical analyses [25-27,40] by
“Statgraphics software systems” (full system 5.25 version
4.0”- Graphics system by statistical graphics corporation
ed. USA. 1989). Values of p ≤ 0.05 were considered
significant.
We used the multivariate statistical procedure that
analyses the correlation between parameters and pro-
duces a matrix of correlation coefficients (that vary from
−1 to +1) and significance (p), allowing a dynamic ana-
lysis of how network components vary with respect to
one another at any moment in time. A positive correl-
ation indicates that the parameters vary in the same dir-
ection, while negative correlation indicates that the
parameters vary in the opposite direction. In fact, the
multivariate statistical procedure that analyses the cor-
relation measures the linear associations between all
parameters; if parameters increase or decrease at the
same time the correlation is positive, while other
changes are considered negative. Statistically independ-
ent parameters have an expected correlation of zero.
Using the principal component analysis (PCA) we plot-
ted the network of vectors obtained by analyzing the data
matrix of correlation coefficients (Figure 1). In the plots
obtained, the angle between vectors is inversely propor-
tional to the degree of correlation between vectors; the
same vector direction indicates a positive correlation/co-
variance, the opposite vector direction indicates a negative
correlation/covariance. This allows a visualization of the
situation under study and is an excellent method for cap-
turing significance from systems biology evaluations [41].
Results
In health, APCs regulate Th cell differentiation and Th cell
network homeostasis through IL6 pathways in women
but through IFNγ pathways in men
Our results confirm that in health, cytokine regulate im-
mune response cell phases through gender specific
pathways.
No significant differences were observed in the levels
of the different types of specific Th cytokines between
men and women apart from IL10, which was higher in
men when PHA stimulus was used (Table 1).
Our results show that APCs regulate Th cell differenti-
ation and Th cell network homeostasis under resting
and activated conditions of the immune system in both
men and women: relationships were found between
APC cytokines (L-cytokines: IFNγ, L6, IL10) and Th cell
cytokines under resting (b-cytokines: IL2, IL4, IFNγ, L6,
IL10) and activated (p-cytokines: IL2, IL4, IFNγ L6,
IL10) conditions (Figure 1). However, this effect appears
to be exerted through IFNγ production in men but
through IL6 production in women (Figure 1).The production of cytokines by cells in resting condi-
tions does not seem to have a specific role in the regula-
tion of Th cells in men (Figure 1, men b-cytokines),
since no significant relationships were observed in either
the 24 h (early regulation) or 72 h culture (late regula-
tion). However in women the linked production of
IL2-IL4 and IFNγ-IL6 Th1/Th2 cytokines appears to
influence regulation (Figure 1, women b-cytokines). Fur-
thermore, this Th1/Th2 IL2 and IL4 inter-regulation in
women appears to have an early and late role in the con-
trol of the Th-cell network since the correlation between
their levels is significant in both the 24 h and 72 h cul-
ture supernatant cytokine assays. The inter-regulation
between IL6 and IFNγ levels is only significant in the 72 h
assay (cytokine assay of the whole blood supernatant after
72 h of cell culture).
Cell cytokine production in activated conditions
appears to have a specific role in the regulation of Th
cell network homeostasis in men and women as signifi-
cant relationships emerged. Figure 1 shows that the early
evolution of activated T cells (24 h, +PHA culture) is
influenced by the positive linked production of IFNγ and
IL10, and IL6 and IL4 cytokines in men, and the nega-
tive linked production of IL6 and IL10 cytokines in
women (Figure 1, p-cytokines). Similarly, the late evolu-
tion of activated T cells (72 h, +PHA culture) seems to
be influenced by the positive linked production of IFNγ
and IL4 in men while by IFNγ and IL6 in women
(Figure 1, p-cytokines).
These results therefore confirm cytokine regulation of
immune response cell phases through gender specific
pathways (Figure 2). Hence, autoimmune disease suscep-
tibility in women could be attributed to the influence of
ΙL6, which plays a key role in autoimmune diseases,
since it is a T cell differentiation switch factor from
Tregs to Th17 cells [14-16]. The greater likelihood of
men developing the primary progressive form, on the
other hand, could be the results of the influence of IFNγ
on Th9 cell inhibition [42] (Figure 2).
Clearly, different gender pathways result in differing
alterations in T cell differentiation and consequently the
generation of different pathological mechanisms and dis-
eases in men and women.
IL6 pathways are involved in Th cell network imbalance
and an increase in neurological deficit in both men
and women suffering from MS
Furthermore, we found that the susceptibility of the
female sex to abnormal autoimmune function can be
attributed to the dominant role of ΙL6 in Tregs imbalance.
To establish whether sexual dimorphism in MS is the re-
sult of sexual dimorphism in the regulation of Th cell net-
work homeostasis in the immune response, independent
cohorts of MS patients (treated and untreated) were
Figure 1 APCs regulate Th cell differentiation and Th cell network homeostasis in both men and women, and this effect appears to be
exerted through IFNγ production in men, but through IL6 production in women. No significant relationships were observed in either the
24 h (early regulation) or 72 h (late regulation) cultures in resting conditions (b-cytokines) in men. In women, relationships were found between
production of IL2-IL4 and IFNγ-IL6 Th1/Th2 cytokines in resting conditions (b-cytokines). The IL2 and IL4 inter-regulation in women was significant in
both the 24 h and 72 h culture supernatant cytokine assays, while the inter-regulation between IL6 and IFNγ levels is only significant in the 72 h assay.
Significant relationships emerged in cell cytokine production in activated (+PHA ) conditions in both, men and women. In the 24 h (early regulation)
PHA culture: positive linked production between IL6 and IL4, and IFNγ and IL10 cytokines (p-cytokines) were found in men, and negative linked
production between IL6 and IL10 cytokines (p-cytokines) were found in women. In the 72 h (late regulation) PHA culture: positive linked production
between IFNγ and IL4 were found in men, while positive linked production between IFNγ and IL6 were found in women (p-cytokines).
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data-driven computational models of disease state. Our
results (Tables 2 and 3) indicate that the IL6 pathway al-
teration is involved in neurological deficit increase and
Tregs imbalance in resting (Figure 3a) and activated
(Figure 3b) conditions in untreated male and femalepatient groups, underlining the autoimmune etiology of
multiple sclerosis (Figure 4). This we concluded from the
fact that cytokine increased levels of IDC/DC IL6 and
TGFβ (the dual biomarker for an increase in Th17 cells
and a fall in Treg cells) were positively related to increases
in neurological deficit (EDSS) (Figures: 3a, 3b and 4).
Table 1 The levels of the different types of specific cytokines in healthy subjects
Whole blood and PBMC supernatants
Healthy subjects
Men
Basic condition PHA LPS
pg/ml Meanwb ± SD Means ± SD Meanwb ± SD Means ± SD Meanwb ± SD
IL10 4,9 ± 13,4 26 ± 40,2 37,6 ± 43,2 93,7 ± 116,7 61,1 ± 96,4
IFNγ 149 ± 194,3 161,8 ± 146,2 1752 ± 2344,5 415,7 ± 389,3 1473,2 ± 2408
IL6 133,3 ± 376,2 390,7 ± 495,7 235,7 ± 303,2 1386,3 ± 2138,3 573,5 ± 714,9
IL2 256 ± 181.8 64,1 ± 78,2 248,7 ± 233,4 290,4 ± 196,8
IL4 15,5 ± 32,2 7,4 ± 10,4 21,9 ± 29 21,8 ± 24,4
Women
Basic condition PHA LPS
pg/ml Meanwb ± SD Means ± SD Meanwb ± SD Means ± SD Meanwb ± SD
IL10 26 ± 46,3 155 ± 180,8 6,9 ± 8,8 143 ± 155,4 72,9 ± 150,3
IFNγ 70,1 ± 110 173,2 ± 74,4 1300,3 ± 2294 1071,1 ± 1102,2 1603 ± 4603
IL6 34,8 ± 67,9 243,3 ± 293,4 104,4 ± 156 1921,5 ± 1654 316,7 ± 322,6
IL2 153,6 ± 140 238,8 ± 247,1 222,4 ± 193 573,4 ± 438,1
IL4 29,4 ± 47,7 24,3 ± 36,6 76,6 ± 115,7 9,7 ± 4,7
Cytokine levels were determined in whole blood (wb) and PBMC supernatant (s) in resting (Basic conditions) and activation conditions after stimulation with PHA
(to study T cell network contribution) and LPS (to evaluate the influence of antigen presenting cells). The levels are expressed as mean ± SD, and statistical
differences between men and women were assessed using the Mann–Whitney U-test or Student’s t-test as appropriate. Production levels of cytokines did not
differ significantly with the exception of IL10 (using the wb method) which was higher in men than in women when PHA stimulus was used (p = 0.038).
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kines), we found that APC IL6 pathways regulate Th cell
differentiation and Th cell network homeostasis by the
positive linked production of IL6 and IL4 in healthy men,
and the negative linked production of IL6 and IL10 cyto-
kines in healthy women. In untreated MS patients, on the
other hand, we found that the relationship in the produc-
tion of IL6 and IL4 in men had changed from positive to
negative while the relationship in the production of IL6 and
IL10 in women had changed from negative to positive
(Figures 3, 4 and 5).
Further confirmation comes from the fact that IL6 pathways
in women and IFNγ pathways in men, are responsible for
the efficacy of IFNβ-therapy in re-establishing Th network
balance and delaying the progression of neurological
disability in treated patients
Then again, the IL6 pathway in women but the IFNγ
pathway in men were responsible for delaying EDSS.
One of our most important findings was that the
re-establishment of immunological (Th cell-network)
and neurological (no increase of EDSS) homeostasis in
treated patient is induced by gender specific cytokine
pathways, since the IL6 vector in women and the IFNγ
vector in men negatively opposed the respective EDSS
vectors (Figure 6a: IDC; 6b: DC). Furthermore, IL6 path-
ways are re-established: the above mentioned relation-
ship between the production of IL6 and IL4 in men,changes from negative (condition of untreated patients)
to positive (condition of healthy subjects). Similarly in
women, the relationship between the production of IL6
and IL10 changes from positive (condition of untreated
patients) to negative (condition of healthy subjects)
(Figures 6a, 6b and 7). Additionally, CD30 pathways are
also re-established: we found that IDC and DC from
treated male and female patients, compared to IDC and
DC from untreated patients, secreted significantly lower
sCD30 levels and significantly higher TGFβ1 levels
(Table 2). Furthermore the relationship between the DC
sCD30 and EDSS production in men, changes from posi-
tive (condition of untreated patients) to negative (condi-
tion of treated patients) (Figure 6a: IDC; 6b: DC).
Likewise in women, the relationship between the IDC
sCD30 and EDSS changes from positive (condition of
untreated patients) to negative (condition of treated
patients) (Figure 6a: IDC; 6b: DC).
In a previous study on MS patients [22] we found that
the “down- or up-regulation” of sCD30 levels, respect-
ively linked to the “up- or down-regulation” of TGFβ
levels, within physiological or pathological ranges, are
dual biomarker for homeostasis or imbalance in im-
munological and neurological pathways and success or
failure of IFNβ therapeutic treatment. The results of this
study confirm the significance of sCD30 and TGFβ as
dual biomarker and identify new gender specific clinical
biomarkers (Figure 8). In fact we found that IDC also
Figure 2 Gender dimorphism of Th cytokine pathways and regulation of Th cell network homeostasis are normally present in the
immune response. The multivariate statistical analysis of the correlation between the levels of Th cytokines (Table 1) confirms the cytokine regulation
of immune response cell phases through gender specific pathways. APC cytokines regulate the resting and activated (PHA) cell phases of immune
response, through gender specific pathways: IL6 pathways is the gender specific pathways in women, but IFNγ pathways is the gender specific
pathways in in men. Consequently, autoimmune disease susceptibility in women could be attributed to the influence of ΙL6, since IL6 prevents the
conversion of naive Th into Treg cells in vivo, by switching Th cell differentiation from Treg to Th17, which plays a key role in autoimmune diseases.
The greater probability of men developing the primary progressive form, conversely, could be the result of the influence of IFNγ on Th9 cell inhibition,
since co-expression of IL-9 and IL-17 was identified as a novel Th17 function in mediating autoimmune tissue destruction, including the CNS.
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http://www.translational-medicine.com/content/10/1/223secreted higher IL10 cytokine levels in men while lower
IL12p40 and IL12p70 cytokine levels in women; DC also
secreted lower IL12p40 cytokine levels in men while
lower IL12p40 and IL12p70 cytokine levels in women
(Table 2). Further confirmation also came from the find-
ing that significant differences between untreated and
treated patient groups were also found in the network
profiles of whole blood Th-cytokine data-driven compu-
tational models of disease state (Table 3): a significant
increase in LPS-IL2, while a significant increase in LPS-
IL4 and decrease in PHA-IFNγ and LPS-TGFβ1 levels
were found in men and women profiles respectively, in
treated and untreated groups.
Dual gender-specific biomarkers for homeostasis in
immunological, neurological and therapeutic pathways,
and translational research for gender-specific drugs
The positive and negative relationships of PHA-
cytokines in healthy men and women (Figure 1, p-cyto-
kines) appear to represent gender specific biomarkersfor homeostasis in the differentiation of activated T cells
(Figure 8).
In fact from Figure 1 it would appear that, in the early
evolution of activated T cells (24 h, +PHA culture), the
positively linked production of IL6 and IL4, IFNγ and
IL10 cytokines are gender specific biomarkers in men,
while the negatively linked production of IL6 and IL10
cytokines are gender specific biomarkers in women
(Figure 1, p-cytokines). Likewise in the late evolution of
activated T cells (72 h, +PHA culture), the positively
linked production of IFNγ and IL4 are gender specific
biomarkers in men, while IFNγ and IL6 are gender spe-
cific biomarkers in women (Figure 1, p-cytokines).
Furthermore (Figure 8), lower sCD30 and higher
TGFβ1 levels in cytokine level profiles, is a positive dual
gender-common biomarker in clinical investigations
looking at IFNβ1a treatment. Gender-specific targets
and biomarkers for male and female therapeutic success
rates are: i) an increase of IL10 levels from IDC in men,
while a fall in IL12p40 and IL12p70 levels from IDC in
Table 2 The levels of cytokines in culture supernatants of IDC and DC in MS patients
Cytokines(pg/ml∘U/ml Treated patients
IDC IDC-LPS
Man Women Man Women
IL10 5.3 ± 0.1a 3.3 ± 0.9 73.9 ± 37.5 41.2 ± 7.9
IL12p70 0 ± 0.02 0.13 ± 0.13b 3.3 ± 3.1 4.5 ± 1.3i
IL12p40 58.2 ± 11.4 35.8 ± 5.9d 3834 ± 796l 3863 ± 260m
TGFβ 22156 ± 1091e 21792 ± 701f 20701 ± 1103n 20164 ± 633p
∘sCD30 7.01 ± 0.4g 6.9 ± 1.1h 13.5 ± 1.1q 14.7 ± 1.1r
Cytokines(pg/ml∘U/ml Untreated patients
IDC IDC-LPS
Man Women Man Women
IL10 0.6 ± 0.6a 1.1 ± 0.5 27.5 ± 19.2 55.8 ± 13.1
IL12p70 0.37 ± 0.9c 2.9 ± 0.6b,c 9.7q ± 6.5 17.1 ± 3.8i
IL12p40 51.9 ± 6.8 63.7 ± 7.3d 5999 ± 277l 5094 ± 647m
TGFβ 16582 ± 813e 16400 ± 575f 14726 ± 642n 14210 ± 601p
∘sCD30 27.2 ± 24g 26.8 ± 5h 36.9 ± 3.2q 38.1 ± 3.5r
Cytokine levels were determined in culture supernatants of IDC (to evaluate the APC influence on immune response in resting conditions) and of DC (to evaluate
the APC influence on immune response in activation conditions). The levels are expressed as mean (or median) ± standard error, as appropriate. Statistical
differences between groups were determined using the Mann–Whitney U-test or Student’s t-test as appropriate: aa p = 0.008; bb p < 0.0001; cc p = 0.03; dd
p = 0.006; ee p = 0.004; ff p < 0.0001; gg p = 0.0007; hh p < 0.0001; ii p = 0.001; ll p = 0.013; mm p = 0.006; nn p = 0.001; pp p = 0.001; qq p = 0.001;
rr p = 0.001.
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http://www.translational-medicine.com/content/10/1/223women; ii) a fall in IL12p40 level from DC in men while
a fall in IL12p40 and IL12p70 levels from DC in women;
iii) an increase in LPS-IL2 in men, and an increase in
LPS-IL4 and a decrease in PHA-IFNγ and LPS-TGFβ1
levels in women, both in whole blood culture (Table 3
and Figure 8).
Discussion
One of the most important epidemiological risk factors
for autoimmune diseases, such as multiple sclerosis, is
the female sex. This susceptibility to abnormal auto-
immune function has mainly gone unexplained but it is
believed that the effects of sex hormones on the immune
system may play an important role. The understanding
of the physiological and pathological mechanisms of
sexual dimorphism in the functioning of the immune
system is therefore of considerable importance and may
pave the way for new therapeutic strategies.
Autoimmune reactions are determined by auto-
reactive T-cells, but are inhibited if Treg cells are
present; the experimental removal of Treg cells has been
shown to lead to autoimmune reactions [43]. Research
has shown that IL6 is critical in preventing the conver-
sion of naive Th cells into Treg cells in vivo by switching
Th cell differentiation from Treg to Th17 [44], inhibiting
the TGFβ-driven expression of Foxp3 and inducing the
expression of ROR-γt transcription factors. Hence, the
IL6 cytokine pathway is a nodal point in the shaping of
an adaptive immune response and we believe that sexual
dimorphism in autoimmune diseases is a result ofdiffering cytokine pathways being involved in the regula-
tion of Th cell network homeostasis.
Hence we focused on sexual dimorphism in relation to
changes in the immune response and, in particular, how
these changes are related to the homeostasis of the cyto-
kine network and regulation pathways of the Th cell net-
work. In a systems biology study we evaluated healthy
subjects and multiple sclerosis patients (IFNβ-treated
and untreated) using cytokines, sCD30 and EDSS para-
meters as biomarkers for Th cell differentiation and
neurological deficit.
Our results confirmed our hypothesis, highlighting
sexual dimorphism in healthy subjects: we found that
IL6 pathways regulate the homeostasis of the Th cell
network in women whilst this homeostasis is regulated
by IFNγ pathways in men (Figures 1 and 2). This means
they could be used as targets and biomarkers for transla-
tional research for the development of gender specific
therapy. Furthermore, the more significant role of ΙL6 in
autoimmune disease with regards to IFNγ explains the
greater susceptibility of women to autoimmune disease.
Our finding that immunological alterations in the Treg
cell pathways are responsible for the increase of EDSS in
both untreated, men and women, MS patients confirms
our conclusions (Figure 4). In fact, IL6 together with
TGFβ pathways, a dual biomarker for Treg/Th17-
network imbalance, were implicated in the EDSS in-
crease in both untreated, men and women groups of MS
patients (Figures 3c and 3d: the vectors of TGFβ, IL6
and EDSS are positively related). In IFNβ-treated
Table 3 The levels of cytokines in whole blood culture supernatants in MS patients
Treated Patients Untreated Patients
Cytokines(pg/ml) Basic condition Basic condition
Men Women Men Women
IL10 2.13 ± 0.4 1.8 ± 0.2 1.5 ± 0.1 1.8 ± 0.2
IFNγ 16.1 ± 5 11.4 ± 3.2 14 ± 2.3 19.8 ± 3.6
IL6 232 ± 227a 10 ± 9.8a 35.8 ± 11.5 12.0 ± 17.5
IL2 10.8 ± 1 8.7 ± 0.9 8.7 ± 3.5 9.4 ± 1.5
IL4 1.1 ± 0.2 1.1 ± 0.1 0.7 ± 0.1 0.7 ± 0.1
IL12p70 9.2 ± 0.9 9.5 ± 0.8 11.2 ± 1.2 8.4 ± 0.7
IL12p40 25.2 ± 2.6 21.6 ± 3 20.1 ± 6.5 20.7 ± 5.1
TGFβ 7324 ± 833 5903 ± 458 10721 ± 5822 5758 ± 386
PHA PHA
Men Women Men Women
IL10 59.7 ± 24.9 23.7 ± 11.8 78 ± 17.4 49.4 ± 30.2
IFNγ 1149.2 ± 570 740 ± 112.9b 2238 ± 904 2102 ± 658b
IL6 759 ± 359 627 ± 109.1 673 ± 427 648.1 ± 153.8
IL2 18.3 ± 5.9 13.9 ± 7.4 20.6 ± 8 21.3 ± 4.1
IL4 9.7 ± 5.3 3.6 ± 1.3 3.6 ± 1.1 1.2 ± 1.5
IL12p70 13.4 ± 2.5 9.9 ± 0.6 9.1 ± 1.5 9.3 ± 0.9
IL12p40 196 ± 105 101.7 ± 15.4 186 ± 82 86.2 ± 15.4
TGFβ 7644 ± 906 6953 ± 583 16029 ± 8457 8612 ± 4630.1
LPS LPS
Men Women Men Women
IL10 144 ± 28.2 215 ± 54.7 181 ± 50 195.5 ± 48.6
IFNγ 135 ± 37.9 71.2 ± 139.4 1131 ± 809.3 263 ± 88.5
IL6 989 ± 89 635.9 ± 112.5 795 ± 173 813.2 ± 123.7
IL2 15.6 ± 3.7c 11 ± 4.4 7.6 ± 1.5c 12 ± 1.6
IL4 1.54 ± 0.5 1.1 ± 0.1d 0.7 ± 0.1 0.7 ± 0.06d
IL12p70 11.5 ± 1.9 8.9 ± 0.8 9.7 ± 0.9 9.1 ± 0.7
IL12p40 416 ± 309 354.4 ± 69.5 1203 ± 664 284.2 ± 87.2
TGFβ 7582 ± 832 7524.6 ± 3492.7e 12669 ± 6570 16984 ± 4854.8e
Levels were determined by whole blood assays in resting conditions (Basic conditions) and after stimulation with PHA (to principally study the activated T cell network
contribution) and LPS (to evaluate the influence of activated antigen presenting cells). The level values are expressed as mean ± SD and statistical differences between
groups were assessed using the Mann–Whitney U-test or Student’s t-test as appropriate: aa p = 0.027; bb p = 0.023; cc p = 0.039; dd p = 0.002; ee p = 0.031.
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but the IFNγ pathway in men were responsible for delay-
ing EDSS (Figure 6a, 6b: the IL6 vector in women, while
the IFNγ vector in men negatively opposed the EDSS
vector).
In recent studies, looking at the role of sCD30 in
immunological and neurological pathways [22], we noted
that the down- or up-regulation of sCD30 levels respect-
ively linked to the up- or down-regulation of TGFβ
levels, within physiological or pathological ranges, repre-
sented a dual biomarker for homeostasis or imbalance in
immunological and neurological pathways and hence for
the success or failure of IFNβ treatment. On this basis,one of our most important findings was that CD30 path-
ways are re-established: we found that a fall in the level
of sCD30 is linked to an increase in TGFβ levels in both
treated patient sex groups compared to untreated
patient sex groups (Table 2).
Hence, sCD30 levels linked to TGFβ levels can be used
as a dual gender target and biomarker in both sexes to
evaluate the success of IFNβ therapy in terms of
re-establishment of Th network balance and the delay of
the progression of neurological disability (EDSS increase)
(Figure 8). Furthermore it is possible to evaluate gender
specific success of therapy by looking at the positive linked
relationships between cytokine levels of IL6-IL4 and IFNγ-
Figure 3 APC analysis in MS untreated patients using IDC, DC and whole blood Th-cytokine data-driven computational models
of disease state. Independent cohorts of MS untreated patients were evaluated, using IDC, DC and whole blood Th-cytokine data-driven
computational models of disease state. We used the multivariate statistical procedure of principal component analysis (PCA) which allowed us to
analyze the relationships between parameters (levels of cytokines, sCD30 and EDDS values) and the behaviour of this multicomponent system as
a network. The levels of cytokines were used as biomarkers of Th differentiation (Treg, Th1, Th9 or Th17) and EDSS was used as biomarker for
neurological deficit. Using the PCA analysis we plotted the network of vectors obtained by analyzing the data matrix of correlation coefficients. In
these plots, the angle between vectors is inversely proportional to the degree of correlation between vectors: the same vector direction indicates
a positive correlation/covariance, the opposite vector direction indicates a negative correlation/covariance. This allows a visualization of the
situation under study and our results indicate that the IL6 pathway is involved in neurological deficit increase and Treg imbalance in resting
(Figure 3a) and activated (Figure 3b) conditions in untreated, male and female patient groups. This we concluded from the fact that cytokine
level increases of IDC/DC IL6 and TGFβ (the dual biomarker for an increase in Th17 cells and a fall in Treg cells) were positively related to
increases in neurological deficit (EDSS) (Figures 3a and 3b).
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Figure 5 IL6 pathways regulate Th cell differentiation and Th cell network homeostasis in healthy men and women. In health APC IL6
pathways regulate Th cell differentiation and Th cell network homeostasis by the positive linked production of IL6 and IL4 in men, and the
negative linked production of IL6 and IL10 cytokines in women. Instead (Figures 3 and 4), in MS untreated patients the relationship between the
production of IL6 and IL4 changes from positive to negative in men, while the relationship between the production of IL6 and IL10 changes
from negative to positive in women.
Figure 4 The IL6 pathway alteration is involved in neurological deficit increase and Tregs imbalance in untreated male and female
patient groups, underlining the autoimmune etiology of multiple sclerosis. Immunological alterations in IL6 pathways are responsible for the
Treg imbalance and increase of EDSS in both sexes in untreated MS patients. In fact, IL6 together with TGFβ pathways, a dual biomarker for Treg/Th17-
network imbalance, were involved in the EDSS increase in both untreated, men and women groups of MS patients (Figures 3c and 3d: the vectors of
TGFβ IL6 and EDSS are positively related). Furthermore, in health, APC IL6 pathways regulate Th cell differentiation and Th cell network homeostasis by
the positive linked production of IL6 and IL4 in men, and the negative linked production of IL6 and IL10 cytokines in women (Figure 1, p-cytokines).
Whereas in untreated MS patients, the relationship between the production of IL6 and IL4 had changed from positive to negative in men, while the
relationship between the production of IL6 and IL10 had changed from negative to positive in women (Figures 3c and 3d).
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Figure 6 APC analysis in MS treated patients using IDC, DC and whole blood Th-cytokine data-driven computational models of disease
state. Re-establishment of IL6 immunological pathways are responsible for the re-establishment of neurological (no increase of EDSS) and
immunological (Th cell-network) homeostasis in treated patients and is induced by gender specific cytokine pathways. In fact , the IL6 vector in
women, and the IFNγ vector in men, negatively opposed their respective EDSS vectors and the relationships between the production of IL6, IL4
and IL6, IL10 reverses to that found in healthy subjects, in both sexes.
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Figure 7 The re-establishment of immunological (Th cell-network) and neurological (no increase of EDSS) homeostasis in treated
patient is induced by gender specific cytokine pathways. The results confirm cytokine regulation of immune response cell phases through
gender specific pathways. Autoimmune disease susceptibility in women could be attributed to the influence of ΙL6, which plays a key role in
autoimmune diseases, since it is a T cell differentiation switch factor from T-regs to Th17 cells. The greater likelihood of men developing the
primary progressive form, on the other hand, could be the results of the influence of IFNγ on Th9 cell inhibition. Targets and biomarkers for
clinical monitoring and translational research for the development of gender specific therapy, were found. sCD30 -TGFβ is a dual clinical
biomarker for both sexes, while IL6-IL10 is a dual clinical biomarker specific for women and IL6-IL4 together with IFNγ-IL10 are dual clinical
biomarkers specific for men. Lastly, differences in the IL10 and IL12p40 cytokine levels in men and IL12p40 and IL12p70 cytokine levels in women,
are also gender specific biomarkers.
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the positive ones between IL2-IL4, IL6-IFNγ in women
(Figure 8).
Overall, our findings underline the need for gender
specific drugs that take into account the differing regula-
tion of the immune response whilst ensuring the same
result: a physiological homeostasis in the resting state, in
the transition to the activation phase and in the return
to the resting state. Obviously these regulatory differ-
ences do not usually have consequences until pathway
alterations occur (Figure 2). In fact, it is well known that
in health, in both sexes, the immune system carries out
its responses and recovers its initial homeostasis, regard-
less of differing initial conditions or evolution. If, how-
ever, these alterations occur in IFNγ and/or IL6 cytokine
pathways, the consequences for men and women, in
terms of pathological mechanisms and disease develop-
ment, are different (Figure 4). The malfunctioning of
gender specific pathways not only compromises the
homeostasis of the immune response, but may also causea pathological polarization of T cell subsets specific to
each sex: IFNγ supports the development of Th1 func-
tions [28] promoting cell mediated immunity, while IL6
cytokine supports Th2 responses where B lymphocytes are
activated and antibody production flourishes. In fact, IFNγ
and IL-6 cytokines were initially classified as the cytokines
responsible for generating Th1 and Th2 type immune
responses respectively. Research in this field, however, has
shown that it is not a single cytokine that determines a
particular response, but rather the interaction of indi-
vidual cytokines within a network. Our results suggest
that a differing susceptibility and clinical course in MS
is caused by different Treg, Th17 and Th9 cell polarization
determined by the TGFβ, IL6, IFNγ and IL4 cytokine
pathway interactions which vary between men and women
(Figure 3 and 4).
These findings are backed up by the results of other
researches indicating that there is a reciprocal develop-
mental relationship between Treg, Th17 and Th9 cells
because: i) TGFβ triggers the expression of Foxp3
Figure 8 Gender specific biomarkers for homeostasis in immunological, neurological and therapeutic pathways. Re-establishment of
immunological and neurological homeostasis in treated patients induced by gender specific cytokine pathways, re-establishes the above
relationships between the production of IL6 and IL4 (from negative, the condition of untreated patients, to positive, the condition of healthy
subjects) in men; similarly in women homeostasis is re-established when the relationship between the production of IL6 and IL10 reverses (from
positive, the condition of untreated patients, to negative, the condition of healthy subjects). Additionally, the significance of sCD30 and TGFβ as a
dual clinical biomarker was confirmed for both sexes and gender specific new clinical biomarkers were identified.
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cells, but ii) IL6 inhibits the TGFβ driven expression of
Foxp3, and TGF β together with IL-6 induce ROR-gt
transcription factor, triggering the developmental pro-
gram of Th17 cells [31], while ii) IL4 also inhibits TGFβ
induction of Foxp3 expression, but TGFβ together with
IL4 induce Th9 cells. On the other hand, co-expression
of IL-9 and IL-17 was identified as a novel Th17 func-
tion in mediating autoimmune tissue destruction
[45,46]. In fact, the IL9 receptor complex is constitu-
tively expressed on astrocytes. IL9 induces astrocytes to
produce CCL-20 but not other chemokines, includingCCL-2, CCL-3, and CXCL-2 [47], suggesting that IL9
induces CCL-20 production by astrocytes to induce the
migration of Th17 cells into the CNS. Treg, Th9 and
Th17 cells have been shown to be important CD4 T cell
subsets in human autoimmune diseases, including
rheumatoid arthritis [48] and multiple sclerosis [49]. So,
it follows that there is sexual dimorphism in the regula-
tion of the Th cell network. IL6 and IFNγ pathway are
the respective male and female pathways used to regu-
late immune and neurological homeostasis and therefore
targets and biomarkers to evaluate gender specific IFNβ
therapy in MS.
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Our results confirm that gender dimorphism in auto-
immune diseases is a result of sexual dimorphism in the
regulation of Th cell network homeostasis in the im-
mune response and the susceptibility of the female sex
to abnormal autoimmune function, such as MS, can be
attributed to the dominant role of ΙL6. The higher prob-
ability of men developing the primary progressive MS
form, on the other hand, can be attributed to the role of
IFNγ in Th9 cell inhibition. Understanding how these
differing pathways lead to disease and how they interfere
with the success of current therapies is of utmost im-
portance in translational medicine and physiological
treatment.
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